ProfoundBio has raised $ 70 million promote two of their oncology drug candidates in clinical trials. The company evolving antibody conjugates are drugs that target cells with antibodies and deliver toxins. This is the same class of drugs sold by biotech giant Seattle Siegen, the previous employer of the CEO of the co-founders of Profound. Baiten ZhaoCOO Tae Khan and technical director Xiao Shang. Sequoia of China tops $ 55 million Series A + Round Series A last summer for Chinese startups Woodinville, Washington, and Suzhou. CEO of Sequoia Capital Lin Yang will be a member of the company’s board of directors.